The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Opdivo (nivolumab) on January 26, 2024. This approval pertains to an efficacy-related supplemental application, indicating an expansion or modification of its approved uses based on new efficacy data.
Background
Nivolumab, marketed as Opdivo, is an established immunotherapy agent. It is also known by other aliases such as opdivo qvantig, nivolumab and relatlimab-rmbw, and nivolumab and hyaluronidase-nvhy. The original Biologics License Application (BLA) for nivolumab is BLA 125554, and this specific event is supplemental application S-122. This indicates a significant update to the drug's approved uses, building upon its established profile and likely expanding its use in a specific patient population or indication.
What this means
This supplemental approval for Opdivo (nivolumab) based on efficacy data means that clinicians will have an expanded or refined treatment option for patients. While the specific details of the new indication or patient population are not provided in this announcement, such approvals typically result from new clinical evidence demonstrating benefit in a previously unaddressed area or an improved treatment paradigm. The FDA's decision to grant a supplemental approval based on efficacy data underscores the continued development and refinement of treatment strategies involving nivolumab. This type of approval often follows successful clinical trials demonstrating a statistically significant and clinically meaningful benefit in a new context, offering healthcare providers additional tools in managing complex diseases.
Source
The information regarding this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA). The approval, identified as BLA 125554 S-122, was documented on January 26, 2024, on accessdata.fda.gov.